- Home
- TGTX vs COMP Comparison
TGTX vs COMP Comparison
Compare TGTX & COMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- COMP
- Stock Information
- Founded
- TGTX 1993
- COMP 2012
- Country
- TGTX United States
- COMP United States
- Employees
- TGTX N/A
- COMP N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- COMP EDP Services
- Sector
- TGTX Health Care
- COMP Technology
- Exchange
- TGTX Nasdaq
- COMP Nasdaq
- Market Cap
- TGTX 5.1B
- COMP 4.2B
- IPO Year
- TGTX 1995
- COMP 2021
- Fundamental
- Price
- TGTX $36.73
- COMP $7.41
- Analyst Decision
- TGTX Strong Buy
- COMP Buy
- Analyst Count
- TGTX 6
- COMP 8
- Target Price
- TGTX $47.50
- COMP $9.75
- AVG Volume (30 Days)
- TGTX 1.9M
- COMP 13.6M
- Earning Date
- TGTX 11-03-2025
- COMP 10-29-2025
- Dividend Yield
- TGTX N/A
- COMP N/A
- EPS Growth
- TGTX N/A
- COMP N/A
- EPS
- TGTX 0.36
- COMP N/A
- Revenue
- TGTX $454,069,000.00
- COMP $6,290,200,000.00
- Revenue This Year
- TGTX $82.22
- COMP $24.26
- Revenue Next Year
- TGTX $47.76
- COMP $12.79
- P/E Ratio
- TGTX $101.18
- COMP N/A
- Revenue Growth
- TGTX 30.96
- COMP 21.23
- 52 Week Low
- TGTX $21.16
- COMP $5.10
- 52 Week High
- TGTX $46.48
- COMP $10.25
- Technical
- Relative Strength Index (RSI)
- TGTX 72.14
- COMP 36.80
- Support Level
- TGTX $34.52
- COMP $7.37
- Resistance Level
- TGTX $37.45
- COMP $8.00
- Average True Range (ATR)
- TGTX 1.10
- COMP 0.41
- MACD
- TGTX 0.59
- COMP -0.14
- Stochastic Oscillator
- TGTX 90.30
- COMP 6.79
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About COMP Compass Inc.
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.